Department of Clinical and Biomedical Sciences, University of Exeter, Exeter, UK.
Division of Population Health, Health Services Research & Primary Care, University of Manchester, Manchester, UK.
Eur J Hum Genet. 2024 Nov;32(11):1456-1464. doi: 10.1038/s41431-024-01654-3. Epub 2024 Aug 1.
Colorectal cancer (CRC) is a leading cause of cancer mortality worldwide. Accurate cancer risk assessment approaches could increase rates of early CRC diagnosis, improve health outcomes for patients and reduce pressure on diagnostic services. The faecal immunochemical test (FIT) for blood in stool is widely used in primary care to identify symptomatic patients with likely CRC. However, there is a 6-16% noncompliance rate with FIT in clinic and ~90% of patients over the symptomatic 10 µg/g test threshold do not have CRC. A polygenic risk score (PRS) quantifies an individual's genetic risk of a condition based on many common variants. Existing PRS for CRC have so far been used to stratify asymptomatic populations. We conducted a retrospective cohort study of 50,387 UK Biobank participants with a CRC symptom in their primary care record at age 40+. A PRS based on 201 variants, 5 genetic principal components and 22 other risk factors and markers for CRC were assessed for association with CRC diagnosis within 2 years of first symptom presentation using logistic regression. Associated variables were included in an integrated risk model and trained in 80% of the cohort to predict CRC diagnosis within 2 years. An integrated risk model combining PRS, age, sex, and patient-reported symptoms was predictive of CRC development in a testing cohort (receiver operating characteristic area under the curve, ROCAUC: 0.76, 95% confidence interval: 0.71-0.81). This model has the potential to improve early diagnosis of CRC, particularly in cases of patient noncompliance with FIT.
结直肠癌(CRC)是全球癌症死亡的主要原因。准确的癌症风险评估方法可以提高早期 CRC 的诊断率,改善患者的健康结果,并减轻诊断服务的压力。粪便免疫化学试验(FIT)用于检测粪便中的血液,广泛用于初级保健,以识别可能患有 CRC 的有症状患者。然而,在诊所中,FIT 的不依从率为 6-16%,并且~90%的症状超过 10μg/g 测试阈值的患者没有 CRC。多基因风险评分(PRS)根据许多常见变异来量化个体患病的遗传风险。迄今为止,用于 CRC 的现有 PRS 已用于对无症状人群进行分层。我们对 UK Biobank 中 50,387 名年龄在 40+岁的有 CRC 症状的参与者进行了回顾性队列研究。使用逻辑回归评估了一种基于 201 个变体,5 个遗传主成分和 22 个其他 CRC 风险因素和标志物的 PRS,以在首次出现症状后 2 年内与 CRC 诊断相关联。将相关变量纳入综合风险模型,并在 80%的队列中进行训练,以预测 2 年内的 CRC 诊断。综合风险模型将 PRS、年龄、性别和患者报告的症状相结合,可预测检测队列中 CRC 的发展(接受者操作特征曲线下面积,ROCAUC:0.76,95%置信区间:0.71-0.81)。该模型有可能改善 CRC 的早期诊断,尤其是在患者不遵守 FIT 情况下。